Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesStarpharma Holdings Ltd

Starpharma Holdings Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.97 USD 0.00(0%)
Last update at 2026-11-10T21:00:00Z
VOLUME
1
Market Cap
240.91M

Momentum Score

…

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Abbotsford, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.82
Low
2.97
High
52 Week Price Range
0.79
Low
5.82
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.97
Dividend Yield
-
Revenue TTM
12.67M
Revenue Per Share
0.30
Gross Profit TTM
0.77M
Debt / Equity
-
ROE
-45.55%
Net Debt
-
ROCE
-64.93%
Diluted EPS TTM
-0.12

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -7.46M -9.99M -8.16M -15.64M -16.15M
Net income -7.46M -9.99M -8.16M -15.64M -16.15M
Selling general administrative 3.20M 3.03M 3.57M 3.77M 3.29M
Gross profit 11.30M 3.69M 7.66M 1.82M 1.91M
Reconciled depreciation 0.91M 1.07M 1.11M 1.19M 1.08M
Ebit - - - -15.77M -16.15M
Ebitda - - - -17.04M -16.63M
Operating income -8.99M -12.00M -10.75M -18.24M -17.71M
Interest expense - - - - 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.62M 0.94M 1.47M 1.27M 0.22M
Net interest income 0.62M 0.94M 1.47M 1.27M 0.22M
Total revenue 12.05M 4.91M 8.29M 2.94M 4.68M
Cost of revenue 0.74M 1.22M 0.63M 1.12M 2.78M
Total other income expense net 0.00M - - 0.14M 0.26M
Net income from continuing ops -7.46M -9.99M -8.16M -15.64M -16.15M
Net income applicable to common shares - - - -15.64M -16.15M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 19.02M 25.42M 36.81M 52.09M 66.17M
Total liab 5.24M 6.42M 8.70M 17.27M 17.78M
Total stockholder equity 13.78M 19.00M 28.12M 34.81M 48.39M
Other current liab - - - 1.05M 1.44M
Common stock - - - 240.72M 240.67M
Capital stock 240.75M 240.75M 240.75M 240.72M 240.67M
Retained earnings -259.82M -252.35M -242.36M -234.20M -218.56M
Other liab - - - 0.05M 0.06M
Cash 11.02M 15.41M 23.36M 35.18M 49.92M
Total current liabilities 5.17M 5.23M 6.66M 14.47M 10.23M
Short long term debt 0.36M 0.44M 0.78M 4.78M -
Other stockholder equity - - - 28.30M 26.29M
Property plant equipment - - - 4.96M 5.52M
Total current assets 17.58M 22.56M 32.92M 47.12M 60.66M
Net tangible assets - - - 34.81M 48.39M
Net receivables 3.65M 4.04M 6.09M 8.23M 7.84M
Long term debt - - - - 4.00M
Inventory 1.66M 1.92M 2.41M 2.77M 2.82M
Accounts payable 2.14M 2.05M 2.73M 6.62M 6.76M
Non currrent assets other 0.00M - - - -
Non current assets total 1.44M 2.86M 3.90M 4.96M 5.52M
Capital lease obligations 0.34M 1.96M 2.75M 3.49M 4.19M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments 0.03M -0.04M -0.09M 0.01M 0.00M
Change to liabilities - - - -0.55M 0.34M
Total cashflows from investing activities - - - -0.61M -0.84M
Net borrowings -0.08M -0.33M -4.00M -0.69M 3.23M
Total cash from financing activities -0.88M -1.13M -4.75M -0.69M 3.23M
Change to operating activities - - - 0.71M -0.01M
Net income -7.46M -9.99M -8.16M -15.64M -16.15M
Change in cash -4.34M -7.93M -11.81M -14.74M -10.58M
Begin period cash flow 15.41M 23.36M 35.18M 49.92M 60.50M
End period cash flow 11.02M 15.41M 23.36M 35.18M 49.92M
Total cash from operating activities - - - -13.53M -13.16M
Depreciation - - - 1.19M 1.08M
Change to inventory - - - 0.05M -1.10M
Change to account receivables - - - -1.26M 0.63M
Change to netincome - - - 1.95M 2.05M
Capital expenditures 0.29M 0.04M 0.09M 0.62M 0.84M
Free cash flow -3.50M -6.80M -7.07M -14.15M -14.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SPHRY
Starpharma Holdings Ltd		 -
-%		 2.97 - 303.03 19.02 24.39 28.44 -6.32
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Abbotsford, Australia.

4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067

61 3 8532 2700

https://starpharma.com

50

Name Title Year Born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA CEO, MD & Exec. Director 1963
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA CFO & Company Sec. NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill Chief Financial and Operations Officer & Company Secretary NA
Ms. Sindy Smith Communications & Investor Relations Manager NA
Ms. Miranda Sowden Director of People & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…